TABLE 2.
Descriptive statistics of patients selected for the analysis
| All patients | HBV | HCV | |
|---|---|---|---|
| Patients enrolled | 2080 | 547 | 1533 |
| Follow-up time in years | |||
| Mean (STD) | 3.37 (1.79) | 3.66 (1.79) | 3.27 (1.77) |
| Median (Q1-Q3) | 3.94 (1.84–4.94) | 4.39 (2.21–5.04) | 3.74 (1.73–4.83) |
| Age, years | |||
| Mean (STD) | 60 (13) | 59 (12) | 61 (13) |
| Median (Q1-Q3) | 61 (50–71) | 60 (51–67) | 62 (50–72) |
| Missing | 2 (0.10%) | 0 (0.00%) | 2 (0.13%) |
| Sex | |||
| M | 1325 (63.70%) | 409 (74.77%) | 916 (59.75%) |
| F | 755 (36.30%) | 138 (25.23%) | 617 (40.25%) |
| BMI, kg/m2 at inclusion in the study | |||
| Mean (STD) | 25.43 (3.91) | 25.44 (3.96) | 25.42 (3.90) |
| Median (Q1-Q3) | 25.16 (22.83–27.58) | 25.34 (23.03–27.47) | 25.14 (22.77–27.64) |
| Missing | 5 (0.24%) | 0 (0.00%) | 5 (0.33%) |
| HBsAg-positive at inclusion in the study | |||
| Yes | — | 512 (93.60%) | — |
| No | — | 35 (6.40%) | — |
| HCVRNA-positive at inclusion in the study | |||
| Yes | — | — | 1391 (90.74%) |
| No | — | — | 142 (9.26%) |
| HCV Genotype | |||
| 1 | — | — | 671 (43.77%) |
| 2 | — | — | 276 (18.00%) |
| 3 | — | — | 129 (8.41%) |
| 4 | — | — | 115 (7.50%) |
| Not typed | — | — | 342 (22.31%) |
| Patients with cirrhosis | |||
| Prevalent cases at inclusion in the study | 1085 (52.16%) | 234 (42.78%) | 851 (55.51%) |
| Incident cases during follow-up | 118 (5.67%) | 18 (3.29%) | 100 (6.52%) |
| Aetiology of cirrhosis | |||
| HBV | 200 (9.62%) | 200 (79.37%) | — |
| HBV + alcohol | 52 (2.50%) | 52 (20.63%) | — |
| HCV | 758 (36.44%) | — | 758 (79.71%) |
| HCV + alcohol | 193 (9.28%) | — | 193 (20.29%) |
| Patients with HCC | |||
| Prevalent cases at inclusion in the study | 447 (21.49%) | 111 (20.29%) | 336 (21.92%) |
| Incident cases during follow-up | 161 (7.74%) | 23 (4.20%) | 138 (9.00%) |
| Patients with CC | |||
| Prevalent cases at inclusion in the study | 716 (34.42%) | 152 (27.79%) | 564 (36.79%) |
| Incident cases during follow-up | 110 (5.29%) | 17 (3.11%) | 93 (6.07%) |
| CPT of CC patients at inclusion in the studya | |||
| A | 789 (95.52%) | 165 (97.63%) | 624 (94.98%) |
| B | 35 (4.24%) | 4 (2.37%) | 31 (4.72%) |
| C | 1 (0.12%) | 0 (0.00%) | 1 (0.15%) |
| Missing | 1 (0.12%) | 0 (0.00%) | 1 (0.15%) |
| Patients with DCb | |||
| Prevalent cases at inclusion in the study | 369 (17.74%) | 82 (14.99%) | 287 (18.72%) |
| Incident cases during follow-up | 167 (8.03%) | 14 (2.56%) | 153 (9.98%) |
| CPT of DCb patients at inclusion in the studyc | |||
| A | 200 (37.31%) | 44 (45.83%) | 156 (35.45%) |
| B | 260 (48.51%) | 36 (37.50%) | 224 (50.91%) |
| C | 59 (11.01%) | 15 (15.63%) | 44 (10.00%) |
| Missing | 17 (3.17%) | 1 (1.04%) | 16 (3.64%) |
| MELD of DCb patients at inclusion in the studyc | |||
| ≤15 | 402 (75.00%) | 69 (71.88%) | 333 (75.68%) |
| >15 | 71 (13.25%) | 13 (13.54%) | 58 (13.18%) |
| Missing | 63 (11.75%) | 14 (14.58%) | 49 (11.14%) |
Abbreviations: BMI, body mass index; CC, compensated cirrhosis; CPT, Child-Pugh-Turcotte; DC, decompensated cirrhosis; HCC, hepatocellular carcinoma; MELD, model for end-stage liver disease; Q1-Q3, 1st quartile – 3rd quartile; STD, standard deviation.
a
% computed on patients with CC.
b
Cirrhotic patients were classified as decompensated if they reported a decompensation event (bleeding, hepatic encephalopathy, ascites) in the past, at enrolment or in the study period.
c
% computed on patients with DC.